https://cantex.com/2019/07/31/chimerix-announces-exclusive-worldwide-license-of-phase-3-ready-cx-01-for-development-in-acute-myeloid-leukemia/ 2020-06-18T17:25:21+00:00 monthly 0.2 https://cantex.com/2020/04/29/chimerix-exclusive-licensee-of-cantex-lead-product-dstat-has-announced-initiation-of-a-phase-2-3-study-of-dstat-formerly-known-as-cx-01-in-acute-lung-injury-for-patients-with-severe-covid/ 2020-06-18T17:34:42+00:00 monthly 0.2 https://cantex.com/2021/02/26/chimerix-exclusive-worldwide-licensee-of-cantexs-investigational-product-dstat-has-announced-promising-topline-results-from-the-first-cohort-of-a-randomized-covid-19-clinical-trial/ 2021-04-28T17:31:01+00:00 monthly 0.2 https://cantex.com/2021/06/22/vtv-therapeutics-and-cantex-pharmaceuticals-announce-strategic-licensing-agreement-for-development-and-commercialization-of-azeliragon-for-treatment-of-cancer/ 2021-06-22T20:10:25+00:00 monthly 0.2 https://cantex.com/2021/09/21/cantex-pharmaceuticals-announces-sale-of-equity-interest-in-chimerix-inc/ 2021-10-08T21:40:36+00:00 monthly 0.2 https://cantex.com/2022/02/24/cantex-to-expand-development-of-its-drug-azeliragon-collaborating-with-harvards-wyss-institute-as-a-treatment-of-covid-19-and-other-inflammatory-lung-diseases-2/ 2023-07-31T19:44:00+00:00 monthly 0.2 https://cantex.com/2023/01/09/cantex-to-expand-development-of-its-drug-azeliragon-collaborating-with-harvards-wyss-institute-as-a-treatment-of-covid-19-and-other-inflammatory-lung-diseases/ 2023-05-26T20:40:15+00:00 monthly 0.2 https://cantex.com/2023/02/27/cantex-receives-fda-study-may-proceed-letter-for-phase-2-clinical-trial-of-azeliragon-for-the-treatment-of-unmethylated-glioblastoma/ 2023-02-27T21:10:12+00:00 monthly 0.2 https://cantex.com/2023/03/06/cantex-and-miami-cancer-institute-announce-fda-clearance-for-a-clinical-trial-investigating-azeliragon-combined-with-stereotactic-radiosurgery-for-the-treatment-of-brain-metastases/ 2023-06-02T21:52:34+00:00 monthly 0.2 https://cantex.com/2023/04/19/cantex-and-michigan-medicine-announce-initiation-of-a-randomized-double-blind-placebo-controlled-phase-2-3-clinical-study-to-determine-the-safety-and-efficacy-of-azeliragon-in-the-treatment-of-patie/ 2023-06-02T21:47:55+00:00 monthly 0.2 https://cantex.com/2023/05/16/cantex-pharmaceuticals-announces-issuance-of-a-pantent-for-azeliragon-as-a-treatment-of-glioblastoma/ 2023-06-14T18:22:30+00:00 monthly 0.2 https://cantex.com/2023/06/01/cantex-pharmaceuticals-obtains-exclusive-worldwide-rights-to-intellectual-property-from-georgetown-university-for-azeliragon-as-a-potential-treatment-of-cancer-related-cognitive-decline/ 2023-06-02T21:10:51+00:00 monthly 0.2 https://cantex.com/2023/06/15/cantex-pharmaceuticals-to-present-at-the-medinvest-oncology-investor-conference-in-boston/ 2023-06-20T21:20:10+00:00 monthly 0.2 https://cantex.com/2023/08/10/cantex-pharmaceuticals-announces-article-published-in-npj-breast-cancer-highlighting-potential-role-of-rage-inhibition-to-prevent-metastasis-in-triple-negative-breast-cancer/ 2023-08-11T18:36:06+00:00 monthly 0.2 https://cantex.com/2023/08/28/cantex-pharmaceuticals-announces-initiation-of-an-investigator-initiated-phase-2-clinical-trial-investigating-azeliragon-combined-with-stereotactic-radiosurgery-for-the-treatment-of-brain-metastases/ 2023-08-28T20:50:47+00:00 monthly 0.2 https://cantex.com/2023/09/18/cantex-pharmaceuticals-and-lenox-hill-hospital-announce-initiation-of-a-phase-2-study-of-rage-inhibitor-azeliragon-as-a-front-line-treatment-for-unmethylated-glioblastoma/ 2023-09-18T15:13:36+00:00 monthly 0.2 https://cantex.com/2023/09/26/cantex-and-allegheny-health-network-announce-initiation-of-a-phase-1-2-study-of-azeliragon-in-patients-refractory-to-first-line-treatment-of-metastatic-pancreatic-cancer/ 2023-09-26T00:37:09+00:00 monthly 0.2 https://cantex.com/2023/09/27/cantex-and-michigan-medicine-announce-initiation-of-a-randomized-double-blind-placebo-controlled-multicenter-phase-3-pivotal-clinical-trial-to-evaluate-the-safety-and-efficacy-of-azeliragon-in-the/ 2023-09-27T13:50:29+00:00 monthly 0.2 https://cantex.com/2024/02/22/cantex-pharmaceuticals-to-participate-in-the-bio-ceo-investor-conference/ 2024-02-23T20:11:46+00:00 monthly 0.2 https://cantex.com/2024/03/19/cantex-pharmaceuticals-to-pacantex-pharmaceuticals-to-present-at-5th-annual-glioblastoma-drug-development-summit/ 2024-03-21T19:11:26+00:00 monthly 0.2 https://cantex.com/2024/05/20/cantex-pharmaceuticals-receives-fda-orphan-drug-designation-for-azeliragon-for-the-treatment-of-pancreatic-cancer/ 2024-05-20T16:08:39+00:00 monthly 0.2 https://cantex.com/2024/05/28/cantex-pharmaceuticals-announces-four-abstracts-to-be-presented-featuring-azeliragon-at-2024-asco-annual-meeting/ 2024-05-28T18:51:30+00:00 monthly 0.2 https://cantex.com/2024/12/09/cantex-pharmaceuticals-receives-fda-orphan-drug-designation-for-azeliragon-for-the-treatment-of-brain-metastasis-from-breast-cancer/ 2024-12-10T20:32:16+00:00 monthly 0.2